BIO-TECHNE Corp Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
BIO-TECHNE Corp (TECH) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $3.10 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-08-24
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2015-06-30 was $12.00K.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2014-06-30 was -$24.00K, a 112.50% decline year-over-year.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2013-06-30 was $192.00K, a 448.57% increase year-over-year.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2013-03-31 was $1.20M.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for fiscal 2026 was $3.10M.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for fiscal 2017 was $1.52M, a 2.00% decline from fiscal 2016.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for fiscal 2016 was $1.55M, a 69.96% increase from fiscal 2015.
- BIO-TECHNE Corp effective income tax rate reconciliation, tax credit, research, amount for fiscal 2015 was $912.00K, a 91.60% increase from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.10M 10-K · filed 2026-08-24 | |||
| 2017-06-30 | $1.52M 10-K · filed 2017-09-07 | |||
| 2016-06-30 | $1.55M 10-K · filed 2017-09-07 | |||
| 2015-06-30 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | $912.00K 10-K · filed 2017-09-07 | ||
| 2015-03-31 | $900.00K 10-Q · filed 2015-05-11 | |||
| 2014-06-30 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | $476.00K 10-K · filed 2016-08-29 | ||
| 2014-03-31 | $500.00K 10-Q · filed 2015-05-11 | |||
| 2013-06-30 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $1.39M derived: sum of 2 quarters · filed 2015-08-31 | $1.39M 10-K · filed 2015-08-31 | |
| 2013-03-31 | $1.20M 10-Q · filed 2013-05-10 | $1.20M 10-Q · filed 2013-05-10 | ||
| 2012-06-30 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $465.00K 10-K · filed 2014-08-29 | ||
| 2012-03-31 | $430.00K 10-Q · filed 2013-05-10 | |||
| 2011-06-30 | $1.33M 10-K · filed 2013-08-29 | |||
| 2010-06-30 | $444.00K 10-K · filed 2012-08-29 | |||
| 2009-06-30 | $1.19M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |